CL2015003434A1 - Composición farmacéutica, su uso y régimen de administración para contracepción a demanda. - Google Patents
Composición farmacéutica, su uso y régimen de administración para contracepción a demanda.Info
- Publication number
- CL2015003434A1 CL2015003434A1 CL2015003434A CL2015003434A CL2015003434A1 CL 2015003434 A1 CL2015003434 A1 CL 2015003434A1 CL 2015003434 A CL2015003434 A CL 2015003434A CL 2015003434 A CL2015003434 A CL 2015003434A CL 2015003434 A1 CL2015003434 A1 CL 2015003434A1
- Authority
- CL
- Chile
- Prior art keywords
- contraception
- pharmaceutical composition
- demand
- administration regime
- regime
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
USO DE UNA COMPOSICION FARMACEUTICA QUE COMPRENDE A) AL MENOS UN ANTAGONISTA DE RECEPTOR EP2 DERIVADO DE INDAZOL Y B) AL MENOS UN INHIBIDOR DE COX ELEGIDO DE INDOMETACINA, DICLOFENACO, MELOXICAM O PIROXICAM, PARA LA CONTRACEPCION A DEMANDA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13169029 | 2013-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2015003434A1 true CL2015003434A1 (es) | 2016-07-22 |
Family
ID=48463871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2015003434A CL2015003434A1 (es) | 2013-05-23 | 2015-11-23 | Composición farmacéutica, su uso y régimen de administración para contracepción a demanda. |
Country Status (20)
Country | Link |
---|---|
US (1) | US9655887B2 (es) |
EP (1) | EP2999469A1 (es) |
JP (1) | JP6370887B2 (es) |
KR (1) | KR20160014598A (es) |
CN (1) | CN105451737B (es) |
AP (1) | AP2015008855A0 (es) |
AR (1) | AR096386A1 (es) |
AU (1) | AU2014270596A1 (es) |
BR (1) | BR112015029214A2 (es) |
CA (1) | CA2913085A1 (es) |
CL (1) | CL2015003434A1 (es) |
EA (1) | EA201592207A1 (es) |
HK (1) | HK1217640A1 (es) |
MA (1) | MA38606A1 (es) |
MX (1) | MX2015016121A (es) |
PH (1) | PH12015502598A1 (es) |
TN (1) | TN2015000511A1 (es) |
TW (1) | TW201522325A (es) |
UY (1) | UY35584A (es) |
WO (1) | WO2014187744A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020021042A2 (pt) | 2018-04-17 | 2021-01-19 | Tempest Therapeutics, Inc. | Carboxamidas bicíclicas e métodos de uso das mesmas |
CN110215447A (zh) * | 2019-06-14 | 2019-09-10 | 上海市计划生育科学研究所 | 甲芬那酸在避孕药物中的应用及其制备的杀精避孕药物 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL319869A1 (en) | 1994-10-24 | 1997-09-01 | Schering Ag | Competitiveprogesterone antagonists for first-need oriented female fertility control |
HU227198B1 (en) | 2001-11-27 | 2010-10-28 | Richter Gedeon Nyrt | Pharmaceutical composition for emergency contraception containing levonorgestrel |
US20040058975A1 (en) * | 2002-06-26 | 2004-03-25 | Schering Ag | Method for fertility control |
AU2006229566B2 (en) | 2005-03-31 | 2011-12-22 | Auckland Uniservices Limited | Tricyclic 1,2,4-triazine oxides and compositions therefrom for therapeutic use in cancer treatments |
DE102005050729A1 (de) | 2005-10-19 | 2007-04-26 | Schering Ag | Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption |
MX2008010193A (es) | 2006-02-10 | 2008-11-27 | Summit Corp Plc | Tratamiento de distrofia muscular de duchenne. |
EP2091329A4 (en) | 2006-12-05 | 2011-02-23 | Univ Nat Chiao Tung | Indazole CONNECTIONS |
WO2009063365A1 (en) * | 2007-11-15 | 2009-05-22 | Pfizer Limited | Azetidines as ep2 antagonists |
CA2758764C (en) | 2009-04-14 | 2017-04-11 | Elizabeth Gray Raymond | Method for on-demand contraception using levonorgestrel or norgestrel |
LT2419108T (lt) | 2009-04-14 | 2016-12-27 | Laboratoire Hra Pharma | Kontracepcijos pagal poreikį būdas |
TW201105655A (en) | 2009-04-22 | 2011-02-16 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
MX2011013959A (es) | 2009-06-23 | 2012-01-25 | Bayer Pharma AG | Composicion farmaceutica para la anticoncepcion de emergencia. |
DE102009049662A1 (de) | 2009-10-13 | 2011-04-14 | Bayer Schering Pharma Aktiengesellschaft | 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten |
US8426392B2 (en) | 2009-12-09 | 2013-04-23 | Laboratoire Hra-Pharma | Method for providing emergency contraception |
US20130045959A1 (en) | 2010-02-01 | 2013-02-21 | Andre Ulmann | Method for late post coital contraception using ulipristal acetate |
TW201326154A (zh) * | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ep2受體拮抗劑之新穎2h-吲唑 |
-
2014
- 2014-05-16 AP AP2015008855A patent/AP2015008855A0/xx unknown
- 2014-05-16 KR KR1020157032972A patent/KR20160014598A/ko not_active Application Discontinuation
- 2014-05-16 TN TN2015000511A patent/TN2015000511A1/en unknown
- 2014-05-16 JP JP2016514342A patent/JP6370887B2/ja not_active Expired - Fee Related
- 2014-05-16 US US14/893,508 patent/US9655887B2/en not_active Expired - Fee Related
- 2014-05-16 CA CA2913085A patent/CA2913085A1/en not_active Abandoned
- 2014-05-16 WO PCT/EP2014/060103 patent/WO2014187744A1/de active Application Filing
- 2014-05-16 MA MA38606A patent/MA38606A1/fr unknown
- 2014-05-16 CN CN201480041669.3A patent/CN105451737B/zh not_active Expired - Fee Related
- 2014-05-16 BR BR112015029214A patent/BR112015029214A2/pt not_active IP Right Cessation
- 2014-05-16 MX MX2015016121A patent/MX2015016121A/es unknown
- 2014-05-16 EP EP14724746.4A patent/EP2999469A1/de not_active Withdrawn
- 2014-05-16 EA EA201592207A patent/EA201592207A1/ru unknown
- 2014-05-16 AU AU2014270596A patent/AU2014270596A1/en not_active Abandoned
- 2014-05-21 TW TW103117811A patent/TW201522325A/zh unknown
- 2014-05-22 AR ARP140102027A patent/AR096386A1/es unknown
- 2014-05-23 UY UY0001035584A patent/UY35584A/es not_active Application Discontinuation
-
2015
- 2015-11-16 PH PH12015502598A patent/PH12015502598A1/en unknown
- 2015-11-23 CL CL2015003434A patent/CL2015003434A1/es unknown
-
2016
- 2016-05-16 HK HK16105550.3A patent/HK1217640A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AR096386A1 (es) | 2015-12-30 |
MA38606A1 (fr) | 2017-03-31 |
US20160089364A1 (en) | 2016-03-31 |
PH12015502598A1 (en) | 2016-02-29 |
JP6370887B2 (ja) | 2018-08-08 |
JP2016518456A (ja) | 2016-06-23 |
BR112015029214A2 (pt) | 2017-07-25 |
MX2015016121A (es) | 2016-03-31 |
UY35584A (es) | 2014-12-31 |
CA2913085A1 (en) | 2014-11-27 |
CN105451737B (zh) | 2018-04-10 |
US9655887B2 (en) | 2017-05-23 |
HK1217640A1 (zh) | 2017-01-20 |
AU2014270596A1 (en) | 2015-12-03 |
WO2014187744A1 (de) | 2014-11-27 |
EP2999469A1 (de) | 2016-03-30 |
AP2015008855A0 (en) | 2015-11-30 |
KR20160014598A (ko) | 2016-02-11 |
TN2015000511A1 (en) | 2017-04-06 |
TW201522325A (zh) | 2015-06-16 |
EA201592207A1 (ru) | 2016-06-30 |
CN105451737A (zh) | 2016-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017000654A1 (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
CL2016000925A1 (es) | Inhibidores de bromodominio | |
CL2016001737A1 (es) | Derivados heterocíclicos bicíclicos como inhibidores de bromodominio | |
CL2015003280A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
CL2016000952A1 (es) | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
CL2020003174S1 (es) | Dispositivo para administración de dosis. | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
CL2015003314A1 (es) | Inhibidores de acc y usos de los mismos | |
MX2016005297A (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos. | |
CL2015002891A1 (es) | Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales. | |
CL2015003635A1 (es) | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos útiles como inhibidores de quinasa. | |
CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
CL2011000976A1 (es) | Compuestos derivados de isonicotinamida y carboxamida, antagonistas de los receptores de orexina; composicion farmaceutica que los comprende; y su uso para la prevencion de un trastorno del sueno. | |
CL2016002495A1 (es) | Derivados de piridina macrocíclicos . | |
CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
BR112017002060A2 (pt) | novo uso | |
CL2015002180A1 (es) | Terapia de combinación para el tratamiento de neumonía nosocomial | |
CL2018003045A1 (es) | Semaglutida en afecciones cardiovasculares. | |
CL2015002113A1 (es) | Compuestos de azetidinloxifenilpirrolidina | |
CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
BR112018008757A2 (pt) | suspensor de liner | |
SV2019005811A (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos | |
CL2015003434A1 (es) | Composición farmacéutica, su uso y régimen de administración para contracepción a demanda. |